University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Margaret A. Tempero, MD

Margaret A. Tempero, MD

Director, UCSF Pancreas Center; Leader, Pancreas Cancer Program; Professor of Medicine, Division of Hematology and Oncology, UCSF
Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science

Cancer Center Program Memberships

Experimental Therapeutics

Research Summary

I am Director, UCSF Pancreas Center and Leader of the UCSF Pancreas Cancer Program. My research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. I was a pioneer in the use of antibody-based therapies and helped develop the fixed dose rate concept for gemcitabine. My group has developed effective gemcitabine combinations and provided a foundation for using CA19-9 as a surrogate for survival in clinical trials, and currently is assessing molecular subtypes and molecular enrichment for selecting new drugs for clinical evaluation. I directed the first GI SPORE devoted to pancreatic cancer when I was on the faculty of the University of Nebraska and subsequently led the NCI-funded U54 Molecular Target Assessment Team at UCSF. I also organized the first Pancreas Cancer Think Tank in 1999 and co-led the NCI sponsored Progress Review Group on Pancreatic Cancer in 2000. I have served as the Chair of the NCCN Guidelines Panel on Pancreatic Cancer since 2000. I also serve as co-chair on the Pancreas Task Force Tissue Acquisition Working Group for the NCI intergroup and co-organized the State of the Science meeting on pancreatic cancer at the NCI.

I have extensive experience in scientific review and administration, training and oversight. I co-directed the AACR/ASCO Methods in Clinical Cancer Research in Vail for three years and spent nine years of service teaching this course and similar courses in Europe and Australia. I was founding Chair of the NCI Clinical Oncology Study Section (CONC) and served as a member and Chair (two-year term) of the NCI Board of Scientific Counselors Subcommittee A. I am on the External Advisory Boards of the Pancreas SPORE at the University of Alabama in Birmingham/University of Minnesota and the Mayo Clinic.

I am, or have been, on the Scientific Advisory Boards of the Lustgarten Foundation, the Pancreatic Cancer Action Network, the V Foundation, The Alberta Canada Cancer Board and the EORTC. I have held many appointments at AACR and ASCO and served as a member of the ASCO Board of Directors and as ASCO President in 2004. I served as a member of the Oncology Drug Advisory Committee for the FDA from 2007-2011. I served as Deputy Director and Interim Director for the UNMC Eppley Cancer Center until 1999, and Chief of the Division of Medical Oncology at UCSF (2000-2007) and Deputy Director and Director of Research Programs at the HDFCCC from 2000 to 2012.

Education

Creighton University, Omaha, NE, B.S., 1969, Medical Technology
University of Nebraska Medical Center, Omaha, NE, M.S., 1974, Clinical Pathology
University of Nebraska Medical Center, Omaha, NE, M.D., 1977, Medicine
University of Nebraska Medical Center, Omaha, NE, Residency, 1980, Internal Medicine
University of Nebraska Medical Center, Omaha, NE, Fellowship, 1983, Oncology


Professional Experience

  • 1983-1987
    Asst. Prof. of Med., Dept. of Internal Medicine, University of Nebraska Medical Center (UNMC), Omaha, NE
  • 1987-1994
    Associate Professor of Medicine, Dept of Internal Medicine, UNMC, Omaha, NE
  • 1983-1985
    Assistant Professor (Courtesy), Eppley Institute for Cancer Research, Omaha, NE
  • 1994-1999
    Professor of Medicine, Dept of Internal Medicine, UNMC, Omaha, NE
  • 1983-1999
    Chief of Oncology/Hematology, V.A. Medical Center, Omaha, NE
  • 1997-1999
    Interim Director, UNMC/Eppley Cancer Center, Omaha, NE
  • 1995-1999
    Deputy Director, UNMC/Eppley Cancer Center, Omaha, NE
  • 1998-2003
    Member, Board of Directors, American Society of Clinical Oncology (ASCO)
  • 1999-present
    Member, Scientific Advisory Board, Pancreatic Cancer Action Network (PanCAN)
  • 2000- 2007
    Chief of Medical Oncology, UCSF School of Medicine
  • 2000- 2012
    Deputy Director, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2000-present
    Professor of Medicine, UCSF School of Medicine
  • 2003-2004
    President, Board of Directors, American Society of Clinical Oncology (ASCO)
  • 2004-present
    Member, Scientific Advisory Board, V Foundation
  • 2012-present
    Member, Mayo Clinic Annual SPORE Scientific Retreat
  • 2012-present
    Director, UCSF Pancreas Center
  • 2012-present
    Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science
  • 2013-present
    Member, External Advisory Board, University of Alabama at Birmingham/University of Minnesota Pancreatic SPORE

Selected Publications

  1. Tempero M. One Size Fits All? Really? J Natl Compr Canc Netw. 2018 Oct; 16(10):1161.
    View on PubMed
  2. Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Fam Cancer. 2018 Sep 28.
    View on PubMed
  3. Kim SS, Ko AH, Nakakura EK, Wang ZJ, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Kim GE. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization? Am J Surg Pathol. 2018 Sep 11.
    View on PubMed
  4. Tempero M. Getting What You Pay For: Finding Value in Cancer Care. J Natl Compr Canc Netw. 2018 Sep; 16(9):1031.
    View on PubMed
  5. Tempero M. Notes From the Other Side. J Natl Compr Canc Netw. 2018 Aug; 16(8):921-922.
    View on PubMed
  6. Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. AJR Am J Roentgenol. 2018 Jul 31; 1-10.
    View on PubMed
  7. Tempero M. Genomic Medicine Takes the Stage, Again! J Natl Compr Canc Netw. 2018 Jul; 16(7):795.
    View on PubMed
  8. Tempero M. Movin' On Up! J Natl Compr Canc Netw. 2018 Jun; 16(6):675.
    View on PubMed
  9. Tempero M. Getting Into the Weeds. J Natl Compr Canc Netw. 2018 May; 16(5):457.
    View on PubMed
  10. Tempero M. Standing Together or Alone. J Natl Compr Canc Netw. 2018 Apr; 16(4):341.
    View on PubMed
  11. Tempero M. Molecular Diagnostics: Another Battle Brewing. J Natl Compr Canc Netw. 2018 Mar; 16(3):225.
    View on PubMed
  12. Tempero M. Extending Our Reach-Will Telemedicine Get Us There? J Natl Compr Canc Netw. 2018 Feb; 16(2):107.
    View on PubMed
  13. Tempero M. Revisiting New Year's Resolutions. J Natl Compr Canc Netw. 2018 Jan; 16(1):1.
    View on PubMed
  14. Tempero M. It's About Time! J Natl Compr Canc Netw. 2017 Dec; 15(12):1443.
    View on PubMed
  15. Tempero MA. Introduction: Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies. Cancer J. 2017 Nov/Dec; 23(6):309.
    View on PubMed
  16. Tempero M. Who's Watching the Kids? J Natl Compr Canc Netw. 2017 Nov; 15(11):1289.
    View on PubMed
  17. Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS. Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. Oncotarget. 2017 Nov 17; 8(58):97769-97786.
    View on PubMed
  18. Doherty GJ, Tempero M, Corrie PG. HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. Future Oncol. 2018 Jan; 14(1):13-22.
    View on PubMed
  19. Tempero M. Serving "a la CAR-T": Value-Based Pricing and Gene Therapy. J Natl Compr Canc Netw. 2017 Oct; 15(10):1179.
    View on PubMed
  20. Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, Womack MS, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. Oncologist. 2017 Dec; 22(12):1427-e129.
    View on PubMed

Go to UCSF Profiles, powered by CTSI